IL153586A0 - Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer - Google Patents
Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancerInfo
- Publication number
- IL153586A0 IL153586A0 IL15358601A IL15358601A IL153586A0 IL 153586 A0 IL153586 A0 IL 153586A0 IL 15358601 A IL15358601 A IL 15358601A IL 15358601 A IL15358601 A IL 15358601A IL 153586 A0 IL153586 A0 IL 153586A0
- Authority
- IL
- Israel
- Prior art keywords
- patients
- cancer
- radiosensitizers
- vitamin
- diagnosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21442700P | 2000-06-28 | 2000-06-28 | |
US21438800P | 2000-06-28 | 2000-06-28 | |
US21438900P | 2000-06-28 | 2000-06-28 | |
PCT/US2001/020444 WO2002000170A2 (en) | 2000-06-28 | 2001-06-28 | Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL153586A0 true IL153586A0 (en) | 2003-07-06 |
Family
ID=27395985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15358601A IL153586A0 (en) | 2000-06-28 | 2001-06-28 | Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1305051A4 (en) |
JP (1) | JP2004501171A (en) |
AU (1) | AU2001271525A1 (en) |
CA (1) | CA2414401A1 (en) |
IL (1) | IL153586A0 (en) |
WO (1) | WO2002000170A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE333288T1 (en) | 2001-05-15 | 2006-08-15 | Faulk Pharmaceuticals Inc | TARGETED RELEASE OF MEDICINAL PRODUCTS FOR THE TREATMENT OF VIRUS INFECTIONS |
US7001991B2 (en) | 2001-05-15 | 2006-02-21 | Faulk Pharmaceuticals, Inc. | Targeted delivery of bioaffecting compounds for the treatment of cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4489710A (en) * | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
US5108987A (en) * | 1982-02-25 | 1992-04-28 | Faulk Ward P | Conjugates of proteins with anti-tumor agents |
GB8519457D0 (en) * | 1985-08-02 | 1985-09-11 | Faulk Ward Page | Tumour imaging agents |
US5792458A (en) * | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
US5208021A (en) * | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
CA2016584C (en) * | 1989-05-17 | 1999-06-29 | Robert S. Greenfield | Anthracycline conjugates having a novel linker and methods for their production |
AUPP405098A0 (en) * | 1998-06-12 | 1998-07-02 | Access Pharmaceuticals Australia Pty Limited | Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals |
-
2001
- 2001-06-28 IL IL15358601A patent/IL153586A0/en unknown
- 2001-06-28 CA CA002414401A patent/CA2414401A1/en not_active Abandoned
- 2001-06-28 AU AU2001271525A patent/AU2001271525A1/en not_active Abandoned
- 2001-06-28 EP EP01950547A patent/EP1305051A4/en not_active Withdrawn
- 2001-06-28 WO PCT/US2001/020444 patent/WO2002000170A2/en active Application Filing
- 2001-06-28 JP JP2002504953A patent/JP2004501171A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1305051A2 (en) | 2003-05-02 |
AU2001271525A1 (en) | 2002-01-08 |
EP1305051A4 (en) | 2007-01-10 |
CA2414401A1 (en) | 2002-01-03 |
WO2002000170A2 (en) | 2002-01-03 |
WO2002000170A3 (en) | 2002-08-08 |
JP2004501171A (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1427403B8 (en) | Valproic acid for the treatment of breast cancer, colon cancer, head and neck cancer, small cell lung carcinoma and cancer of the blood cells in combination with irradiation | |
NO20015584L (en) | Long-lasting insulin-tropic peptides and conjugates and use in the manufacture of medicaments for treatment | |
WO2004062604A3 (en) | Treatment of cancer with 2-deoxyglucose | |
EP1586338A3 (en) | The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices | |
HUP0102489A2 (en) | Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body | |
IL182352A0 (en) | The use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743 | |
ATE235513T1 (en) | OPIOID CONJUGATES WITH ENDOGENE CARRIER PROTEINS | |
TW200630089A (en) | Treatment methods | |
WO1999056723A3 (en) | Hemoglobine-haptoglobin complexes for targeted drug delivery | |
DE69817602D1 (en) | DRUG ADMINISTRATION SYSTEM WITH TWO-STAGE TARGETING | |
Alexiou et al. | Therapeutic efficacy of ferrofluid bound anticancer agent | |
IL153586A0 (en) | Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer | |
DE602005026510D1 (en) | Anthracyclinderivate | |
IL159770A0 (en) | Calcium salts with cytotoxic activity | |
AR029160A1 (en) | THE USE OF PEGILATED INTERFERON-ALFA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF RENAL CELL CARCINOMA, A KIT AND THE USE OF IT | |
Hryniuk | Importance of chemotherapy scheduling: pieces of the puzzle | |
Hervonen et al. | Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study | |
RU2003124139A (en) | METHOD FOR PROLONGED DRUG THERAPY | |
Gallo et al. | AS Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res., 56: 4686-4693, 1996 | |
Kmietowicz | Chemotherapy better tolerated when matched to body's rhythm | |
Chin et al. | Forthcoming articles and issues | |
Lee et al. | Dental and nutritional management of the head and neck cancer patient | |
Sparano et al. | Increasing the efficacy of 5-fluorouracil with interferons: preclinical, clinical, and pharmacokinetic studies | |
Lee et al. | Dental and nutritional management of the head and neck cancer patient | |
RU99103901A (en) | METHOD FOR MEDICINAL TREATMENT OF MALIGNANT TUMORS |